Characteristicsa | Overall (N = 391) |
---|---|
Females (%) | 297 (76.0%) |
Age at Phase I (years) | 56.0 ± 9.0 |
Age at Phase III (years) | 68.0 ± 8.4 |
Cardiovascular risk factors at Phase I | Â |
Smoking status | Â |
 Never (%) | 241 (61.6%) |
 Former (%) | 93 (23.8%) |
 Current (%) | 57 (14.6%) |
Body mass index (kg/m2) | 31.4 ± 6.2 |
Hypertension | 249 (63.7%) |
Type 2 diabetes | 63 (16.1%) |
Total cholesterolb (mg/dl) | 208.56 ± 50.4 |
Low-density lipoprotein cholesterolc (mg/dl) | 121.8 (42.8) |
Statin use (%) | 18 (4.6%) |
Atherosclerosis measures at Phase III | Â |
Coronary artery calcification score, median (IQR) | 18.7 (0–195.7) |
Abdominal aorta calcification score, median (IQR) | 500.8 (18.9–1800.5) |
Ankle–brachial index, median (range)d | 0.985 (0.474–1.274) |
Multi-site atherosclerosis score, median (IQR) (range 0–12) | 5 (2–7) |
Methylation risk scores at Phase I | Â |
MRSCACe | 0.92 ± 0.85 |
MRScarotid | − 3.52 ± 0.81 |
DNAm age measures at Phase I | Â |
HorvathAge (years) | 52.8 ± 8.9 |
HannumAge (years) | 46.2 ± 9.5 |
PhenoAge (years) | 42.7 ± 11.5 |
GrimAge (years) | 52.8 ± 7.9 |